This clinical trial is for men and women with unresectable locally-advanced or metastatic triple-negative breast cancer. There is currently a need for more effective treatment methods for this disease.
The study drug that is being investigated in this clinical trial, SGN-LIV1A, is a type of drug called an antibody drug conjugate (ADC). Another study drug, Pembrolizumab, is a type of drug called a checkpoint inhibitor, or CPI. CPIs are antibodies that stick to and block a protein on cancer cells that helps them survive. This study is being done to test the safety and side effects of SGN-LIV1A and pembrolizumab when used together.
You will be given SGN-LIV1A and pembrolizumab in 3-week cycles. If your cancer is stable or gets better, you may get up to 35 cycles with pembrolizumab. There is no set limit for how many cycles of SGN-LIV1A you can receive. After you have stopped getting these drugs, we will ask you to have follow up visits and/or follow-up phone calls every 3 months or until the study is closed.